List of Excipients in Branded Drug OMNISCAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GE Healthcare Inc	OMNISCAN	gadodiamide	0407-0690	CALDIAMIDE SODIUM
GE Healthcare Inc	OMNISCAN	gadodiamide	0407-0690	HYDROCHLORIC ACID
GE Healthcare Inc	OMNISCAN	gadodiamide	0407-0690	SODIUM HYDROXIDE

Last updated: August 9, 2026

Omniscan, the gadolinium-based MRI contrast agent containing gadodiamide, has limited value as a conventional branded pharmaceutical opportunity because its active-ingredient and core formulation protections have expired, its U.S. commercial position has weakened, and safety restrictions limit use in patients with severe renal impairment. The strongest commercial opportunities are in generic supply, hospital-ready packaging, supply-chain reliability, and formulation improvements that preserve the established excipient system rather than materially altering gadodiamide exposure.

Omniscan Excipient Strategy and Commercial Opportunities

What is Omniscan and what excipients does it contain?

Omniscan is an injectable extracellular MRI contrast agent containing gadodiamide. The product is supplied at 287 mg/mL gadodiamide, equivalent to 0.5 mmol/mL of gadolinium, in a sterile aqueous solution for intravenous administration.[1]

The principal formulation components are:

Component	Function
Gadodiamide	Gadolinium-containing paramagnetic contrast agent
Caldiamide sodium	Excess chelating ligand intended to reduce free gadolinium exposure
Water for Injection	Vehicle
Hydrochloric acid and/or sodium hydroxide	pH adjustment

The labeled pH is generally maintained within the mildly acidic to near-neutral range. The formulation does not rely on antimicrobial preservatives, which is appropriate for a high-volume parenteral diagnostic product administered through sterile single-use containers.[1]

The most commercially important excipient is caldiamide sodium. It is not a conventional bulking agent or stabilizer. It is a chelating ligand included to bind residual free gadolinium and improve formulation control. Any reformulation that changes its concentration, purity, or interaction with gadodiamide must be evaluated for free-gadolinium levels, osmolality, pH, viscosity, chemical stability, and toxicological performance.

What is the excipient strategy for gadodiamide injection?

The preferred strategy is a conservative, low-excipient formulation. Gadodiamide is an injectable coordination complex, so the formulation should avoid unnecessary excipients that could alter metal-ligand equilibrium or create new regulatory burdens.

Core formulation objectives

A commercially viable Omniscan alternative should target:

1. Stable gadodiamide concentration through shelf life.
2. Controlled free gadolinium levels.
3. Acceptable osmolality and viscosity for intravenous administration.
4. Compatibility with glass vials, polymer containers, syringes, and elastomeric closures.
5. Low particulate and extractables risk.
6. Sterility assurance without preservatives.
7. Consistent performance across manufacturing sites.

The formulation should retain water for injection and pH adjustment as the basic excipient platform. Caldiamide sodium should remain the principal chemical-risk control unless a sponsor has strong data supporting a different chelation strategy.

Why excipient minimalism is commercially useful

A minimal excipient composition reduces:

• Compatibility testing.
• Extractables and leachables work.
• Labeling complexity.
• Parenteral toxicology requirements.
• Manufacturing deviations.
• Regulatory comparability risk.
• Hospital pharmacy concerns about unfamiliar additives.

A new formulation with surfactants, buffers, tonicity agents, antioxidants, or antimicrobial preservatives would need a clear commercial benefit. The addition of sodium chloride, for example, might support osmolality adjustment but could increase ionic strength and affect stability or compatibility. A phosphate or citrate buffer could improve pH control but would add an interaction risk in a metal-containing formulation. Surfactants are difficult to justify unless they solve a demonstrated adsorption, container, or precipitation problem.

What formulations are protected by Omniscan’s historical intellectual property?

The historical intellectual property around gadodiamide was directed primarily to the gadolinium complex, ligand chemistry, pharmaceutical compositions, and use as an MRI contrast agent. The original patent estate is mature, and the central composition and use protections have expired or are no longer meaningful barriers to generic development.

The principal commercial protection did not come from a modern, differentiated excipient platform. Omniscan’s formulation is relatively simple and uses established injectable-product technology. The remaining value therefore lies in execution: manufacturing quality, container systems, regulatory equivalence, supply continuity, and institutional contracting.

Patent and exclusivity position

Protection category	Commercial assessment
Gadodiamide composition patents	Historical protections; core terms have expired
MRI diagnostic-use patents	Historical protections; unlikely to block current generic entry
Basic aqueous formulation	Limited standalone blocking value
Caldiamide sodium use in formulation	Potential process or formulation know-how, but weak as a broad barrier without unexpired claims
Container and closure configuration	May support narrow claims if separately patented
Manufacturing process	Possible trade-secret value; generally difficult to enforce against independent development
FDA regulatory exclusivity	No meaningful current branded exclusivity identified for Omniscan
Biosimilar exclusivity	Not applicable; Omniscan is a small-molecule drug product

A definitive freedom-to-operate review still depends on jurisdiction, claim scope, terminal disclaimers, prosecution history, and any later patents covering manufacturing or packaging. The broad commercial conclusion is clear: patent expiry does not prevent a generic gadodiamide product from entering the market.

What is the FDA regulatory status of Omniscan?

Omniscan was approved by the FDA as an intravenous MRI contrast agent. Its approved uses include contrast enhancement for central nervous system, thoracic, abdominal, and pelvic MRI examinations, subject to the product labeling and patient-specific risk assessment.[1]

The product carries major renal-risk restrictions related to nephrogenic systemic fibrosis, or NSF. The FDA labeling identifies increased risk in patients with acute kidney injury or severe chronic kidney disease. The product is generally avoided in patients with an estimated glomerular filtration rate below 30 mL/min/1.73 m² unless the clinical circumstances justify use.[1,2]

The FDA has also required class-wide warnings concerning gadolinium retention. Omniscan is a linear gadolinium-based contrast agent, and linear agents have generated particular scrutiny because of higher gadolinium retention relative to certain macrocyclic agents.[3]

Regulatory implications for an Omniscan generic

A generic sponsor must address:

• Pharmaceutical equivalence.
• Assay and impurity profile.
• Free gadolinium control.
• pH and osmolality.
• Sterility and bacterial endotoxin limits.
• Container-closure integrity.
• Stability under labeled storage conditions.
• Extractables and leachables.
• Administration-device compatibility.
• Bioequivalence or the applicable FDA approach for an injectable contrast agent.

Because the product is administered intravenously and is not generally evaluated through a conventional oral bioequivalence study, the regulatory package will focus heavily on pharmaceutical equivalence, product quality, manufacturing controls, and comparative physicochemical data.

What is the Orange Book status of Omniscan?

Omniscan and gadodiamide products are subject to the FDA’s discontinued-drug and approved-product databases rather than a current, commercially significant brand-exclusivity position. The central issue for an ANDA applicant is whether any active patents or regulatory exclusivities remain listed against a relevant reference product at the time of filing.

The Orange Book should be reviewed for:

• The reference listed drug designation.
• Any listed patents.
• Patent-use codes.
• Product discontinuation status.
• Available dosage forms and strengths.
• Whether a currently marketed reference product is available for ANDA comparison.

No biosimilar pathway applies because gadodiamide is a chemically defined small-molecule drug product, not a therapeutic biologic.

When does Omniscan lose exclusivity and what does that mean commercially?

Omniscan’s core exclusivity has already lapsed. The product is therefore exposed to generic substitution, institutional tendering, and price competition.

The economic opportunity depends less on premium pricing than on manufacturing cost and supply reliability. MRI contrast agents are purchased by hospitals, imaging centers, group purchasing organizations, and government entities. Procurement decisions often prioritize:

• Unit price.
• Reliable allocation.
• Availability of multiple vial sizes.
• Low back-order risk.
• Automated injector compatibility.
• Technical support.
• Consistent lot release.
• Reimbursement and formulary acceptance.

An entrant with no meaningful formulation differentiation can still compete if it provides lower cost and dependable supply. A sponsor should not assume that a new excipient alone will command a premium.

What generic entry risks exist for Omniscan?

Generic entry risk is high from an IP perspective but moderated by manufacturing and clinical-use barriers.

High-risk areas for the originator

The originator faces:

• ANDA filings based on the established formulation.
• Institutional conversion to lower-cost gadodiamide products.
• Private-label or contract-manufactured supply.
• Price competition from alternative gadolinium agents.
• Continued substitution toward macrocyclic agents in higher-risk patients.
• Reduced demand in sites that favor agents with lower gadolinium-retention concerns.

High-risk areas for a generic entrant

A generic entrant faces:

• Difficulty obtaining consistent high-purity gadodiamide starting material.
• Tight control requirements for free gadolinium.
• Sterile manufacturing capacity constraints.
• Complex container and closure validation.
• Limited market growth for linear gadolinium agents.
• Hospital resistance to switching contrast products.
• Safety-driven preference for alternative agents.
• Potential litigation over narrow process, formulation, or packaging patents.

The principal barrier is not the expired active-ingredient patent. It is the ability to manufacture a sterile, chemically controlled, regulatorily acceptable product at a price that supports hospital contracting.

How strong is the Omniscan patent estate?

The current blocking strength of the Omniscan patent estate is weak. The original composition and use claims are old, and the formulation does not appear to depend on a highly differentiated delivery technology.

Patent strength can be separated into four levels:

Patent layer	Strength
Core gadodiamide molecule	Low after expiry
Basic aqueous injection	Low unless a narrow unexpired claim applies
Caldiamide sodium formulation parameters	Moderate only if claims are active, narrow, and technically difficult to design around
Manufacturing and packaging	Potentially moderate, but usually limited to specific processes or configurations

A sponsor evaluating licensing or acquisition should avoid paying a premium for historical Omniscan patents without confirming live claims, remaining term, enforceability, and commercial relevance in target jurisdictions.

Which companies are challenging or competing with Omniscan?

The competitive field includes other gadolinium-based contrast agents rather than only direct gadodiamide generics.

Product	Active agent	Manufacturer or originator	Competitive relevance
Omniscan	Gadodiamide	GE HealthCare, historically marketed through GE Healthcare entities	Reference product; linear agent
Magnevist	Gadopentetate dimeglumine	Bayer, historically	Older linear extracellular agent
ProHance	Gadoteridol	Bracco	Macrocyclic alternative
Gadavist	Gadobutrol	Bayer	Macrocyclic alternative with broad MRI use
Dotarem	Gadoterate meglumine	Guerbet	Macrocyclic alternative
MultiHance	Gadobenate dimeglumine	Bracco	Linear ionic agent with hepatobiliary properties
Eovist	Gadoxetate disodium	Bayer	Hepatobiliary-focused contrast agent

The competitive threat comes from two directions. Generic gadodiamide products can reduce price. Macrocyclic agents can reduce the clinical relevance of gadodiamide where physicians prioritize lower gadolinium dissociation and retention profiles.

What excipient-based commercial opportunities exist?

1. Generic gadodiamide injection

The most direct opportunity is an ANDA product using the established excipient system. Commercial success would depend on manufacturing economics, container availability, and contracting rather than novel chemistry.

Potential presentations include:

• Single-dose vials.
• Prefilled syringes.
• Pharmacy bulk packages where permitted.
• Injector-compatible containers.
• Unit-dose presentations for outpatient imaging centers.

2. Ready-to-use syringe systems

A prefilled syringe could reduce pharmacy handling and dosing errors. The product would require container compatibility, dose accuracy, sterility, plunger performance, and injector validation.

The commercial benefit is strongest in high-throughput imaging centers. The opportunity is weaker where hospitals already use automated contrast injectors with bulk vial workflows.

3. Low-waste packaging

Gadodiamide is weight- and volume-sensitive, and unused contrast is frequently discarded after a patient encounter. Packaging designed around common adult dosing ranges could reduce waste.

Possible approaches include:

• Smaller single-use fills.
• Dose-specific presentations.
• Dual-volume packaging.
• Syringe configurations compatible with automated injectors.
• Improved residual-volume performance.

Packaging claims may create limited patent value, but the business benefit can be real if the format lowers per-procedure cost.

4. Supply-chain differentiation

A second-source supplier with validated manufacturing in more than one region could compete on shortage protection. Hospitals and group purchasing organizations may value continuity more than modest formulation differences.

This opportunity requires:

• Multiple qualified raw-material suppliers.
• Redundant sterile fill-finish capacity.
• Strong container-closure supply.
• Controlled cold-chain or ambient logistics, depending on stability data.
• Rapid lot-release testing.
• Regulatory readiness for manufacturing-site changes.

5. Improved impurity control

A sponsor could differentiate through tighter specifications for:

• Free gadolinium.
• Uncomplexed ligand.
• Degradation products.
• Metals and elemental impurities.
• Particulate matter.
• Container-derived contaminants.

This is more likely to support regulatory confidence and quality positioning than premium pricing. The claim strategy would usually rely on process know-how, validated controls, and manufacturing documentation rather than broad formulation patents.

6. Hospital-specific contract manufacturing

A contract manufacturer could provide gadodiamide injection under private-label arrangements, subject to applicable FDA requirements and customer contracting. The opportunity is strongest for imaging networks seeking supply diversification without building internal sterile manufacturing capability.

What manufacturing and IP barriers affect commercial entry?

The critical manufacturing steps include preparation of the gadolinium complex, control of ligand stoichiometry, purification, sterile filtration or aseptic processing, vial or syringe filling, and container-closure integrity testing.

Key technical risks

• Incomplete complexation.
• Free gadolinium formation during storage.
• Interaction with elastomeric components.
• Adsorption to polymer syringes.
• Precipitation or visible particulates.
• pH drift.
• Loss of assay through container interaction.
• Sterility failures during aseptic processing.
• Variability in caldiamide sodium quality.

The strongest defensible know-how may involve raw-material specifications, complexation conditions, impurity purge, sterile filtration, and packaging compatibility. These controls can be maintained as trade secrets, although they do not prevent a capable competitor from developing an independent process.

What patent litigation and Paragraph IV risks affect Omniscan?

Paragraph IV risk is limited because the core Omniscan patent estate is mature. A generic applicant could still face litigation if a sponsor asserts later patents covering:

• Narrow concentration ranges.
• Specific caldiamide sodium ratios.
• Container systems.
• Prefilled syringe configurations.
• Automated injector interfaces.
• Manufacturing processes.
• Stability improvements.
• Particular medical-use populations.

A Paragraph IV dispute would be commercially meaningful only if the asserted patent has an unexpired term and covers the proposed product. Historical Omniscan patents alone are unlikely to create a durable launch barrier.

No major current litigation or settlement agreement should be assumed solely from the existence of the branded product. Any investment decision should distinguish expired historical disputes from live patent litigation affecting current U.S. market entry.

How does Omniscan compare with macrocyclic MRI contrast agents?

Factor	Omniscan/gadodiamide	Macrocyclic agents
Chelate structure	Linear	Macrocyclic
Formulation complexity	Relatively simple aqueous injection	Product-specific aqueous systems
Gadolinium stability	Lower than macrocyclic agents	Generally higher thermodynamic and kinetic stability
Renal-risk restrictions	Important, especially in severe renal impairment	Still require renal-risk assessment
Retention concerns	Commercial disadvantage	Often preferred where retention concerns drive selection
Generic opportunity	Potentially attractive on cost	Larger clinical market but stronger established competition
Excipient differentiation	Limited	More opportunity through delivery and packaging, but higher development cost

The major strategic weakness of Omniscan is clinical positioning, not excipient technology. A low-cost gadodiamide product may gain volume in price-sensitive settings, but a premium product based only on excipient changes is unlikely to displace macrocyclic agents.

What revenue exposure and commercial scenarios apply?

Omniscan revenue is exposed to both generic erosion and therapeutic substitution. The relevant market is the broader MRI contrast market, not only gadodiamide.

Scenario analysis

Scenario	Commercial outcome
Basic generic vial	Low-margin volume business; dependent on tenders and supply reliability
Prefilled syringe	Moderate differentiation; may reduce waste and handling costs
Injector-optimized package	Niche opportunity in high-throughput imaging centers
Reformulated low-osmolality product	High development and regulatory burden; uncertain clinical benefit
Macrocyclic-like stability claim without new active	Difficult to substantiate and unlikely to overcome active-agent limitations
Dual-source hospital contract	Attractive if supply shortages or allocation persist
Private-label manufacturing	Potentially scalable, but dependent on regulatory and quality infrastructure

The most credible near-term opportunity is a cost-efficient generic with reliable supply and optimized packaging. The least attractive strategy is a heavily reformulated product that adds excipients without improving clinical performance or procurement economics.

Key Takeaways

• Omniscan contains gadodiamide, caldiamide sodium, water for injection, and pH-adjusting agents.
• Caldiamide sodium is the key functional excipient because it controls residual free gadolinium.
• The core Omniscan patent and exclusivity position is mature and does not provide a strong current barrier to generic entry.
• A preservative-free, minimal-excipient formulation is the lowest-risk development strategy.
• The strongest commercial opportunities are generic supply, prefilled syringes, low-waste packaging, injector compatibility, and manufacturing redundancy.
• Omniscan remains commercially disadvantaged against macrocyclic agents because of gadolinium retention and stability concerns.
• The principal entry barriers are sterile manufacturing, impurity control, container compatibility, and hospital contracting.
• New excipients alone are unlikely to justify premium pricing or create a durable market position.

FAQs

Can caldiamide sodium be replaced in an Omniscan generic?

Replacement is technically possible but commercially unattractive without a clear safety, stability, or manufacturing advantage. Caldiamide sodium is closely tied to control of free gadolinium and would require extensive comparative chemistry and toxicology support if replaced.

Is Omniscan a biologic requiring a biosimilar application?

No. Gadodiamide is a chemically defined small-molecule contrast agent. A follow-on product would generally use the applicable generic drug pathway rather than the biosimilar pathway.

Can a new Omniscan formulation avoid gadolinium-retention concerns?

Changing excipients is unlikely to eliminate the intrinsic stability and retention concerns associated with a linear gadolinium complex. A meaningful improvement would likely require a different active chelate, which would be a new product rather than a simple Omniscan reformulation.

Are Omniscan prefilled syringes patentable?

A specific syringe, injector interface, closure system, or low-residual-volume configuration may support narrow patent claims if it is novel and non-obvious. The commercial value would depend on actual use in imaging centers and the remaining patent term.

Is a generic gadodiamide product commercially attractive?

It can be attractive as a manufacturing and procurement opportunity, particularly where hospitals seek lower prices or a second source. The opportunity is weaker as a premium branded product because the active ingredient is mature and macrocyclic agents compete on safety perception.

References

1. U.S. Food and Drug Administration. (2023). Omniscan (gadodiamide injection) prescribing information.
2. U.S. Food and Drug Administration. (2010). FDA drug safety communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction.
3. U.S. Food and Drug Administration. (2018). FDA warns that gadolinium-based contrast agents are retained in the body; requires new class warnings.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
5. International Council for Harmonisation. (2023). ICH Q3D(R2): Guideline for elemental impurities.